Use Cases
Longevity
Healthy Ageing and Longevity
The category with the largest gap between ambition and evidence, and the one where the quality of the underlying research matters most.
EExperimental / Limited EvidenceReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- The goal is usually stated as extending healthy years rather than treating a condition, which makes it structurally hard to measure.
- Epitalon's reputation rests on telomerase and pineal-regulation claims plus reported survival effects in animals.
- NAD+ and glutathione are used on the basis that both decline with age and both sit at the centre of energy metabolism and antioxidant defence.
The evidence
What the research shows
- Epitalon's key studies come overwhelmingly from one Russian research group and have not been independently replicated — the single biggest weakness in the longevity peptide literature.
- NAD+ precursor trials in humans consistently raise NAD+ levels, but have not demonstrated clinical benefit in healthy adults.
- Intravenous and injected glutathione raises blood levels; evidence that this changes health outcomes is thin, and the skin-lightening use it is often marketed for has documented safety concerns.
- Longevity outcomes require decades to measure, so no compound in this category can honestly claim human outcome evidence today.
- Cartalax has almost no independent published research of any kind.
Reported use
How it is reported to be used
- Reported use is cyclical — short courses once or twice a year — a pattern taken directly from the Russian peptide literature rather than from any dose-finding study.
- Reported benefits are diffuse: sleep, energy, wellbeing. These are precisely the outcomes most vulnerable to expectancy effects.
- Because there is no measurable endpoint, users generally cannot tell whether anything is happening.
Our reading
Evidence verdict
EExperimental / Limited EvidenceVery little published research of any kind. Discussion is largely theoretical or anecdotal.
Experimental. Little independent published research, no human outcome data, and endpoints that are inherently hard to measure.
Before you read further
Cautions and open questions
- Research from a single group without independent replication should be treated as preliminary regardless of how striking the reported findings are.
- The interventions with actual human longevity evidence remain unglamorous: sleep, exercise, not smoking, blood pressure and lipid control.
- No safety data exist for repeated annual courses over decades.
Sources
Referenced research
- Animal study
Epitalon and telomerase activity: published research
- Limitations
- Findings originate largely from a single research group; independent replication is lacking.
- Systematic review
NAD+ precursor supplementation in humans: trial evidence
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases